2012: CureMeta, a Boston-based Therapeutic Oncology Biotech, was founded to discover novel targets and develop novel antibody therapeutic drugs to treat aggressive and metastatic cancers and provide real and meaningful benefits to patients suffering from these diseases. A proprietary Antibody Discovery platform was utilized to generate antibodies to stem cell targets involved in cancer metastasis and utilize these new antibodies to develop Antibody-Drug Conjugate therapeutics.

2019: A US patent was received on our lead therapeutic antibody, Bstrongximab, a therapeutic monoclonal antibody specific to the cancer target TRA-1-60, an embryonic target present cancers including gastric, prostate, and pancreatic cancer cells. We filed 11 patents on antibodies that were not found in normal tissues for human cancers.

2024: We have developed a proprietary and productive antibody discovery platform and have generated many monoclonal antibodies. Our lead therapeutic antibody is now a humanized IgG1, Bstrazumab, and our lead therapeutic Antibody-Drug-Conjugate is now CM-14, Bstrazumab conjugated to the toxic payload MMAE.

“CM-14 is a first-in-class cancer ADC targeted for the treatment
of patients with advanced and metastatic solid-tumor cancers.”